Critical Path Institute's Patient-Centered Evidence Consortium
CLINICAL OUTCOME ASSESSMENTS
Founded in 2008, the Patient-Centered Evidence (PCE) Consortium, formerly the Patient-Reported Outcome (PRO) Consortium, maximizes impact of patient-centered evidence on drug development, regulatory access, and treatment decision making, through rigorous scientific methods, standards, and multistakeholder collaboration.
Since its inception, the consortium has achieved 5 qualification statements for 6 PRO measures. The consortium seeks to make these qualified measures and others that have been developed available for use in clinical trials.
On this site, you will find information regarding available measures covering different therapeutic areas. Details about each measure, including target populations, measurement descriptions, translations and licensing requirements, can be accessed through our measures page.
LICENSING
Licensing fees are assessed on a per trial/per measure basis for commercial use.
-
Patient-Centered Evidence Consortium Member Firms:
-
First Language $1000 USD
-
Each Additional/Available Language $500 USD
-
-
Non-Member Organizations
-
First Language $4000 USD
-
Each Additional/Available Language $2000 USD
-
Non-commercial use is assessed on a case-by-case basis for appropriateness and applicability.
To license a measure, please complete our licensing form. All of the information provided in the form will be kept strictly confidential. For questions, please contact us.